Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Letter to the Editor

Functional cure of chronic hepatitis B encounters resmetirom

Nai-Bin Yang, Wai-Kay Seto, Ming-Hua Zheng

Clin Mol Hepatol. 2024;30(3):580-581. Published online April 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0301

View: 2008 Download: 96 Web of Science: 1

Review

MAFLD: How is it different from NAFLD?

Cameron Gofton, Yadhavan Upendran, Ming-Hua Zheng, Jacob George

Clin Mol Hepatol. 2023;29(Suppl):S17-S31. Published online November 29, 2022

DOI: https://doi.org/10.3350/cmh.2022.0367

View: 18575 Download: 1,310 Web of Science: 119 Crossref: 138

Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review

Lei Miao, Jing Xu, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng

Clin Mol Hepatol. 2022;28(4):725-738. Published online March 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0015

View: 5662 Download: 262 Web of Science: 13 Crossref: 15

Original Article

Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients

Wen-Yue Liu, Xiaofang Zhang, Gang Li, Liang-Jie Tang, Pei-Wu Zhu, Rafael S. Rios, Kenneth I. Zheng, Hong-Lei Ma, Xiao-Dong Wang, Qiuwei Pan, Robert J. de Knegt, Luca Valenti, Mohsen Ghanbari, Ming-Hua Zheng

Clin Mol Hepatol. 2022;28(2):183-195. Published online November 28, 2021

DOI: https://doi.org/10.3350/cmh.2021.0301

View: 6346 Download: 219 Web of Science: 5 Crossref: 6

Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis

Gang Xu, Yu-Min Wang, Miao-Miao Ying, Sui-Dan Chen, Zong-Rui Li, Hong-Lei Ma, Ming-Hua Zheng, Jian Wu, Chunming Ding

Clin Mol Hepatol. 2021;27(2):329-345. Published online January 20, 2021

DOI: https://doi.org/10.3350/cmh.2020.0261

View: 7895 Download: 236 Web of Science: 16 Crossref: 17

Review

Bioactive metabolites: a clue to the link between MASLD and CKD?

Wen-Ying Chen, Jia-Hui Zhang, Li-Li Chen, Christopher D. Byrne, Giovanni Targher, Liang Luo, Yan Ni, Ming-Hua Zheng, Dan-Qin Sun

Received September 9, 2024 Accepted October 18, 2024

DOI: https://doi.org/10.3350/cmh.2024.0782 [Accepted]

View: 569 Download: 79

1 |

Viewed By 5098	MAFLD: How is it different from NAFLD?
Viewed By 5072	Examining the therapeutic landscape of beta-blockers in portal hypertension
Viewed By 4498	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4474	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4363	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Cited By 248	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 198	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 145	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 138	MAFLD: How is it different from NAFLD?
Cited By 113	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search